Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Dividend Harvesting Portfolio Week 175: $17,500 Allocated, $1,566.24 In Projected Dividends
09:00am, Thursday, 11'th Jul 2024
Markets started the 2nd half of 2024 strong, with S&P up 1.69% and Nasdaq up 3.29%. Earnings season approaching, with the banking sector first, followed by the Magnificent Seven. Dividend Harvesting P
3 Undervalued Stocks Ready for a Breakout This Summer
12:00pm, Wednesday, 10'th Jul 2024
As the second half of 2024 unfolds, main Wall Street indices are reaching new highs. The Nasdaq 100 index soared more than 20% year-to-date, and the S&P 500 saw an all-time high with a 16% surge.
Want $1,000 in Reliable Dividend Income? Invest $11,800 in these 3 Ultra-High-Yield Dividend Stocks.
05:23am, Wednesday, 10'th Jul 2024
Bristol Myers Squibb's earnings outlook revision was disturbing but hardly a reason to avoid the Big Pharma stock. With a yield above 10%, PennantPark Floating Rate Capital is hard for income-seeking
The 7 Best Warren Buffett Stocks to Buy in July 2024
07:40am, Tuesday, 09'th Jul 2024
I just read an article that quoted billionaire hedge fund manager, David Einhorn, as saying value investing was dead. Since I'm writing about the best Warren Buffett stocks, that thought piqued my int
3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now
05:21am, Tuesday, 09'th Jul 2024
Bristol Myers Squibb upset investors with a big acquisition-related expense, but its pharmaceutical business is stronger than ever. Vici Properties is a real estate investment trust that collects rent
Top Dividend Stocks To Buy In July 2024? 2 In Focus
03:26pm, Monday, 08'th Jul 2024
Dividend stocks for your July 2024 watchlist.
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
06:59am, Monday, 08'th Jul 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day.
3 Defensive Stocks to Buy During the Market Dip
06:43am, Monday, 08'th Jul 2024
Despite markets reaching new heights recently, many defensive stocks with reliable and consistent demand are still experiencing their own market dip. They have pulled back as investors repositioned in
5 Relatively Secure And Cheap Dividend Stocks To Invest In - July 2024
09:30am, Saturday, 06'th Jul 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July
05:07am, Saturday, 06'th Jul 2024
Pfizer's been raising its dividend payout for 15 years, and a heap of new products could help it continue the streak. The largest publicly traded business development company, Ares Capital offers inve
Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now
07:17am, Friday, 05'th Jul 2024
24/7 Insights Wounded blue chip stocks can offer huge total return potential.
Going Beyond Morningstar's 10 Best Value Stocks List
11:57pm, Monday, 01'st Jul 2024
Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P
Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges
08:11am, Monday, 01'st Jul 2024
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition
Buy The Drop On These 6% Dividend Value Picks
08:10am, Saturday, 29'th Jun 2024
AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices
Is Bristol Myers Squibb Stock a Buy?
07:34am, Friday, 28'th Jun 2024
Bristol Myers has delivered some underwhelming returns for investors in the past decade. The company's future is uncertain as it faces multiple patent cliffs.
